The Board of Directors of Enzymatica AB has appointed Claus Egstrand as CEO of Enzymatica. Claus Egstrand assumes his new position at the latest on January 1, 2022 and succeeds acting CEO Therese Filmersson, who returns to the role as CFO. Claus Egstrand has a long experience from pharmaceutical and medtech companies, such as Merck & Co, Pfizer, Stryker Corporation, Pharmacia, and Johnson&Johnson/Merck Pharmaceuticals. Claus Egstrand joined Enzymatica in 2017 as Chief Commercial Officer, and he was later appointed Chief Operating Officer. Claus Egstrand's main focus has been the company's international expansion. When Claus Egstrand assumes the position as CEO, Bengt Baron returns to his previous role as Chairman and Therese Filmersson returns to her previous role as CFO - Chief Financial Officer, and at the same time she is appointed Deputy CEO since Claus Egstrand is domiciled outside the EU (England).